Fig 1.
Consolidated reporting standard for trials diagram of patient flow.
Table 1.
Baseline characteristics of three groups.
Fig 2.
Detailed procedures of the MVM for expiration strength grades and breath-hold time.
Fig 3.
Positive rate of HUTT and the incidence of recurrent syncope in NVM and MVM group.
(A) positive rate of HUTT at baseline and after 30 days treatment in NMV and MVM groups, (B) The Kaplan-Meier curves for recurrent syncope rates during 12 months follow-up in NMV and MVM groups. ** P<0.01.
Fig 4.
HUTT and the incidence of recurrent syncope in all VVS patients.
The Kaplan-Meier curves for recurrent syncope rates during 12 months follow-up of patients from HUTT positive and HUTT negative groups.
Table 2.
Risk factors of recurrent syncope during the follow-up 12 months obtained from Cox proportional hazards models post 30 days intervention.
Fig 5.
HRV analysis of CON, NVM and MVM groups at baseline and after 30 days treatment. * P<0.05; ** P<0.01.
Fig 6.
(A) ROC curve of SDNN after 30 days treatment, (B) ROC curve of SDANN after 30 days treatment.